Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

α2A Adrenergic Receptor Activation Inhibits Epileptiform Activity in the Rat Hippocampal CA3 Region

Chris W. D. Jurgens, Hana M. Hammad, Jessica A. Lichter, Sarah J. Boese, Brian W. Nelson, Brianna L. Goldenstein, Kylie L. Davis, Ke Xu, Kristin L. Hillman, James E. Porter and Van A. Doze
Molecular Pharmacology June 2007, 71 (6) 1572-1581; DOI: https://doi.org/10.1124/mol.106.031773
Chris W. D. Jurgens
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hana M. Hammad
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica A. Lichter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah J. Boese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian W. Nelson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brianna L. Goldenstein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kylie L. Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ke Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristin L. Hillman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James E. Porter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Van A. Doze
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Norepinephrine has potent antiepileptic properties, the pharmacology of which is unclear. Under conditions in which GABAergic inhibition is blocked, norepinephrine reduces hippocampal cornu ammonis 3 (CA3) epileptiform activity through α2 adrenergic receptor (AR) activation on pyramidal cells. In this study, we investigated which α2AR subtype(s) mediates this effect. First, α2AR genomic expression patterns of 25 rat CA3 pyramidal cells were determined using real-time single-cell reverse transcription-polymerase chain reaction, demonstrating that 12 cells expressed α2AAR transcript; 3 of the 12 cells additionally expressed mRNA for α2CAR subtype and no cells possessing α2BAR mRNA. Hippocampal CA3 epileptiform activity was then examined using field potential recordings in brain slices. The selective αAR agonist 6-fluoronorepinephrine caused a reduction of CA3 epileptiform activity, as measured by decreased frequency of spontaneous epileptiform bursts. In the presence of βAR blockade, concentration-response curves for AR agonists suggest that an α2AR mediates this response, as the rank order of potency was 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine (UK-14304) ≥ epinephrine >6-fluoronorepinephrine > norepinephrine ⋙ phenylephrine. Finally, equilibrium dissociation constants (Kb) of selective αAR antagonists were functionally determined to confirm the specific α2AR subtype inhibiting CA3 epileptiform activity. Apparent Kb values calculated for atipamezole (1.7 nM), MK-912 (4.8 nM), BRL-44408 (15 nM), yohimbine (63 nM), ARC-239 (540 nM), prazosin (4900 nM), and terazosin (5000 nM) correlated best with affinities previously determined for the α2AAR subtype (r = 0.99, slope = 1.0). These results suggest that, under conditions of impaired GABAergic inhibition, activation of α2AARs is primarily responsible for the antiepileptic actions of norepinephrine in the rat hippocampal CA3 region.

Footnotes

  • This investigation was supported in part by North Dakota Experimental Program to Stimulate Competitive Research (ND EPSCoR) through the National Science Foundation (NSF) grants EPS-0132289 and EPS-0447679 (to V.A.D.), NSF Faculty Early Career Development (Career) Award 0347259 (to V.A.D.), National Institutes of Health grant 2P20-RR016471 from the Biomedical Research Infrastructure Networks (BRIN) program and National Institutes of Health grant 5P20-RR017699 from the Centers of Biomedical Research Excellence (COBRE) program (to V.A.D. and J.E.P.). Additional student support was provided by an Epilepsy Foundation Predoctoral Research Training Fellowship (to C.W.J.), an American Epilepsy Society Predoctoral Research Training Fellowship (to K.L.H.), a Doctoral Dissertation Assistantship from ND EPSCoR (to K.L.H.), an Advanced Undergraduate Research Award (AURA) from ND EPSCoR (to S.J.B), an Explorations in Biomedicine Under graduate Summer Research Fellowship for Native Americans from the American Physiological Society (to K.L.D.), and an Undergraduate Summer Research Training Fellowship from the University of North Dakota Office of the Associate Vice President for Medical Research (to B.L.G. and J.A.L.).

  • Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

  • doi:10.1124/mol.106.031773.

  • A preliminary report of these findings was presented at the 2005 annual meeting of the Society for Neuroscience; November 12–16, 2005; Washington DC, and the 2006 annual meeting of the American Society for Pharmacology and Experimental Therapeutics, Neuropharmacology Session, April 1–5, San Francisco, CA.

  • J.E.P. and V.A.D contributed equally to this work.

  • ABBREVIATIONS: CNS, central nervous system; CA, cornu ammonis; NE, norepinephrine; LTP, long-term potentiation; EPI, epinephrine; AR, adrenergic receptor; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid; MK-912, (2S-trans)-1,3,4,5′,6,6′,7,12b-octahydro-1′,3′-dimethyl-spiro[2H-benzofuro[2,3-a]quinolizine-2,4′(1′H)-pyrimidin]-2′(3′H)-one hydrochloride; ARC-239, 2-[2-(4-(2-methoxyphenyl)piperazin-1-yl-)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride; BRL-44408, 2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole maleate; ACSF, artificial cerebrospinal fluid; RT-PCR, reverse transcription polymerase chain reaction; 6FNE, 6-fluoronorepinephrine; PHE, (R)-(–)-phenylephrine; UK-14304, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine.

  • ↵1 Current affiliation: Department of Pharmaceutical Sciences, School of Pharmacy, North Dakota State University, Fargo, North Dakota.

    • Received October 13, 2006.
    • Accepted March 6, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 71 (6)
Molecular Pharmacology
Vol. 71, Issue 6
1 Jun 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
α2A Adrenergic Receptor Activation Inhibits Epileptiform Activity in the Rat Hippocampal CA3 Region
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

α2A Adrenergic Receptor Activation Inhibits Epileptiform Activity in the Rat Hippocampal CA3 Region

Chris W. D. Jurgens, Hana M. Hammad, Jessica A. Lichter, Sarah J. Boese, Brian W. Nelson, Brianna L. Goldenstein, Kylie L. Davis, Ke Xu, Kristin L. Hillman, James E. Porter and Van A. Doze
Molecular Pharmacology June 1, 2007, 71 (6) 1572-1581; DOI: https://doi.org/10.1124/mol.106.031773

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

α2A Adrenergic Receptor Activation Inhibits Epileptiform Activity in the Rat Hippocampal CA3 Region

Chris W. D. Jurgens, Hana M. Hammad, Jessica A. Lichter, Sarah J. Boese, Brian W. Nelson, Brianna L. Goldenstein, Kylie L. Davis, Ke Xu, Kristin L. Hillman, James E. Porter and Van A. Doze
Molecular Pharmacology June 1, 2007, 71 (6) 1572-1581; DOI: https://doi.org/10.1124/mol.106.031773
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Use-Dependent Relief of A-887826 Inhibition
  • Benzbromarone Relaxes Airway Smooth Muscle via BK Activation
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics